Cullinan Therapeutics Reports Promising Outcomes from Zipalertinib Phase 2b Study for Non-Small Cell Lung Cancer
Saturday, 14 September 2024, 01:15
Positive Data from Zipalertinib Study
Cullinan Therapeutics has announced updated results from Module C of their pivotal Phase 2b study for Zipalertinib, focusing on non-small cell lung cancer. The findings reveal a consistent objective response rate of 40% in patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This therapeutic option showcases a manageable safety profile, emphasizing its potential as a pivotal treatment in oncology.
Study Highlights
- Consistent objective response rate of 40%.
- Manageable safety profile enhances the viability of Zipalertinib.
- Targets patients with non-small cell lung cancer effectively.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.